News & Events about Axonics Modulation Technologies Inc.
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report first quarter 2023 financial results after the close of trading on Monday, May 1. Axonics will host a...
Axonics, Inc. (NASDAQ:AXNX Get Rating) CEO Raymond W. Cohen sold 40,736 shares of Axonics stock in a transaction dated Friday, January 13th. The shares were sold at an average price of $65.94, for a total transaction of $2,686,131.84. Following the sale, the chief executive officer now owns ...
Latest Ratings for AXNX
DateFirmActionFromTo Feb 2022SVB LeerinkMaintainsOutperform Feb 2022Morgan StanleyMaintainsOverweight Jan 2022Morgan StanleyMaintainsOverweight
View More Analyst Ratings for AXNX
View the Latest Analyst Ratings
read more...
Shares of Axonics, Inc. (NASDAQ:AXNX Get Rating) have earned an average recommendation of Moderate Buy from the eleven ratings firms that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will participate in the Piper Sandler Healthcare Conference on December 1, 2022. Axonics is scheduled to present at 11:00 a.m...